University of Oxford

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private

Established: 1096-01-01

Employees: 10K

Market Cap: -

Website: http://www.ox.ac.uk

Clinical Trials

A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.

Phase 3

Recruiting

Conditions: Plasmodium Falciparum Malaria (Uncomplicated)

Interventions: Drug: Artemether-lumefantrine + placebo (AL+PBO)
Drug: Artemether-lumefantrine+ Amodiaquine (AL+AQ)
Drug: Artesunate-mefloquine+placebo (AS-MQ+PBO)
Drug: Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)

First Posted Date: 2019-04-23

Last Posted Date: 2024-03-27

Lead Sponsor: University of Oxford

Target Recruit Count: 3240

Registration Number: NCT03923725

Locations: 🇨🇩
Kinshasa School of Public Health, Kinshasa, Congo, The Democratic Republic of the
🇳🇪
Epicentre Niger, Niamey, Niger
🇷🇼
College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda

and more 5 locations

Quality of Life in Pancreas Transplantation

Conditions: Diabetes Mellitus
Quality of Life

Interventions: Procedure: Solid Organ Pancreas Transplantation with or without Kidney Transplantation

First Posted Date: 2019-04-19

Last Posted Date: 2021-09-29

Lead Sponsor: University of Oxford

Target Recruit Count: 110

Registration Number: NCT03921593

Locations: 🇬🇧
Oxford University Hospital NHS Foundation Trust, Oxford, Oxfordshire, United Kingdom

Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer

Phase 1

Completed

Conditions: Locally Advanced Rectal Cancer

Interventions: Biological: Enadenotucirev
Drug: Capecitabine
Radiation: Radiotherapy

First Posted Date: 2019-04-16

Last Posted Date: 2023-06-28

Lead Sponsor: University of Oxford

Target Recruit Count: 13

Registration Number: NCT03916510

Locations: 🇬🇧
Velindre Cancer Centre, Cardiff, United Kingdom
🇬🇧
Royal Marsden NHS Foundation Trust, London Borough of Sutton, United Kingdom
🇬🇧
Beatson West Of Scotland Cancer Centre, Glasgow, United Kingdom

and more 1 locations

Investigating Immune Responses to Aerosol BCG Challenge in Healthy UK Adults

Phase 1

Active, not recruiting

Conditions: Tuberculosis

Interventions: Biological: BCG Danish
Other: Saline placebo

First Posted Date: 2019-04-11

Last Posted Date: 2024-01-03

Lead Sponsor: University of Oxford

Target Recruit Count: 94

Registration Number: NCT03912207

Locations: 🇬🇧
Oxford University Hospitals- John Warin Ward, University of Oxford, Oxford, Oxfordshire, United Kingdom
🇬🇧
Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Churchill Hospital, Oxford, Oxfordshire, United Kingdom

VAC063C: A Study to Assess Repeat Blood-stage P. Falciparum Infection

Not Applicable

Completed

Conditions: Malaria

Interventions: Biological: Blood-stage controlled human P. falciparum malaria infection

First Posted Date: 2019-04-08

Last Posted Date: 2019-04-08

Lead Sponsor: University of Oxford

Target Recruit Count: 11

Registration Number: NCT03906474

Locations: 🇬🇧
CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom

Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso

Phase 1

Completed

Conditions: Malaria,Falciparum

Interventions: Biological: R21 adjuvanted with 25mcg Matrix-M
Biological: Rabies Vaccine
Biological: R21 adjuvanted with 50mcg Matrix-M

First Posted Date: 2019-04-01

Last Posted Date: 2023-09-07

Lead Sponsor: University of Oxford

Target Recruit Count: 450

Registration Number: NCT03896724

Locations: 🇧🇫
Institut de Recherche en Sciences de la Sante - Clinical Research Unit of Nanoro (IRSS-URCN), Nanoro, Burkina Faso

Study to Compare Blood Levels of Ceftriaxone Given by Suppository or Injection.

Phase 1

Not yet recruiting

Conditions: Healthy

Interventions: Drug: A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)
Drug: B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)
Drug: C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)

First Posted Date: 2019-03-29

Last Posted Date: 2023-07-19

Lead Sponsor: University of Oxford

Target Recruit Count: 37

Registration Number: NCT03895567

Locations: 🇹🇭
Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

Cardiovascular Function and Ribavirin Pharmacokinetics and Pharmacodynamics in Patients With Lassa Fever

Terminated

Conditions: Lassa Fever

Interventions: Drug: Ribavirin

First Posted Date: 2019-03-26

Last Posted Date: 2022-07-06

Lead Sponsor: University of Oxford

Target Recruit Count: 2

Registration Number: NCT03889106

Locations: 🇸🇱
Kenema Government Hospital, Kenema, Sierra Leone

Understanding How Salmonella Typhi Infects Humans (Bottlenecks)

Not Applicable

Completed

Conditions: Salmonella Typhi Infection

Interventions: Biological: Salmonella Typhi challenge

First Posted Date: 2019-03-26

Last Posted Date: 2022-02-09

Lead Sponsor: University of Oxford

Target Recruit Count: 11

Registration Number: NCT03889067

Locations: 🇬🇧
Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Oxford, Oxfordshire, United Kingdom

Neonatal Hyperbilirubinaemia in the Democratic Republic of Congo

Completed

Conditions: Neonatal Hyperbilirubinemia

First Posted Date: 2019-03-19

Last Posted Date: 2020-12-14

Lead Sponsor: University of Oxford

Target Recruit Count: 306

Registration Number: NCT03880591

Locations: 🇨🇩
Kinshasa Medical Oxford Research Unit, Kinsasa, Congo, The Democratic Republic of the

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy